Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
236. |
ECCT/20/04/03 | 518 & 525-SHAN6™ Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants. Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age |
Principal Investigator(s) 1. Bernhards Ogutu 2. Godfrey Allan Otieno 3. Videlis Nduba 4. Lucy Chepkurui Koech 5. samuel Gurrion Ouma 6. Janet Oyieko Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county) 5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county) 6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county) 7. CRDR_Siaya Annex(Back-up site) (Siaya county) |
View |
237. |
ECCT/20/05/03 | A5381 Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment |
Principal Investigator(s) 1. Victor Mudhune Site(s) in Kenya Kisumu Clinical Research Center |
View |
238. |
ECCT/20/06/06 | E-MOTIVE FORMATIVE Understanding effectiveness of implementation of a postpartum haemorrhage initial response bundle |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Mwingi Sub county (level 4 ) hospital (Kitui county) 2. Nyeri Level 5 Hospital (Nyeri county) 3. Garissa county referral hospital (Garissa county) 4. Embu Level 5 hospital (Embu county) 5. TIGONI LEVEL 4 HOSPTIAL (Kiambu county) 6. Meru Teaching and Referral Hospital (Meru county) 7. Kitengela Sub county Hospital (Kajiado county) 8. Kakamega County Government Referral Hospital (Kakamega county) 9. Mbagathi County Hospital (Nairobi City county) 10. St. Mary\'s Mission Hospital (Nairobi City county) |
View |
239. |
ECCT/20/06/07 | Quality of Oxytocin and TXA Quality of Oxytocin and Tranexamic acid in selected facilities in six countries |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Mwingi Sub county (level 4 ) hospital (Kitui county) 2. Nyeri Level 5 Hospital (Nyeri county) 3. Garissa county referral hospital (Garissa county) 4. Embu Level 5 hospital (Embu county) 5. TIGONI LEVEL 4 HOSPTIAL (Kiambu county) 6. Meru Teaching and Referral Hospital (Meru county) 7. Kitengela Sub county Hospital (Kajiado county) 8. Mbagathi County Hospital (Nairobi City county) 9. Kakamega County Government Referral Hospital (Kakamega county) 10. St. Mary\'s Mission Hospital (Nairobi City county) |
View |
240. |
ECCT/20/11/02 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (IAVI C100) |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya 1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county) 2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county) |
View |